{"nctId":"NCT02480114","briefTitle":"Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy","startDateStruct":{"date":"2015-07"},"conditions":["Malignant Head and Neck Neoplasm","Mucositis","Radiation-Induced Disorder"],"count":79,"armGroups":[{"label":"Arm I Standard of Care","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Educational Intervention","Other: Pain Therapy","Other: Quality-of-Life Assessment","Other: Questionnaire Administration","Drug: Oxycodone/Acetaminophen","Drug: Hydrocodone/Acetaminophen","Drug: Fentanyl","Drug: Ibuprofen","Drug: Magic Mouthwash"]},{"label":"Arm II Standard of Care Plus Gabapentin","type":"EXPERIMENTAL","interventionNames":["Other: Educational Intervention","Drug: Gabapentin","Other: Pain Therapy","Other: Quality-of-Life Assessment","Other: Questionnaire Administration","Drug: Oxycodone/Acetaminophen","Drug: Hydrocodone/Acetaminophen","Drug: Fentanyl","Drug: Ibuprofen","Drug: Magic Mouthwash"]}],"interventions":[{"name":"Educational Intervention","otherNames":["Education for Intervention"]},{"name":"Gabapentin","otherNames":["Gralise","Neurontin","1-(aminomethyl) cyclohexaneacetic Acid, 60142-96-3,"]},{"name":"Pain Therapy","otherNames":["Analgesia","Pain Control","Pain Management","Pain"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]},{"name":"Questionnaire Administration","otherNames":[]},{"name":"Oxycodone/Acetaminophen","otherNames":["Percocet"]},{"name":"Hydrocodone/Acetaminophen","otherNames":["Lortab","Vicodin"]},{"name":"Fentanyl","otherNames":["Duragesic"]},{"name":"Ibuprofen","otherNames":["Motrin","Advil"]},{"name":"Magic Mouthwash","otherNames":["Miracle Mouthwash","First-Mouthwash BLM","First-BXN Mouthwash"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically proven cancer of the head and neck cancer\n* Stage 3 or 4\n* Planned primary or adjuvant chemoradiation therapy\n* Willing and able to provide informed consent\n* English speaking\n\nExclusion Criteria:\n\n* Currently on gabapentin\n* Prior non-tolerance of gabapentin\n* History of seizure disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))","description":"The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.26","spread":null},{"groupId":"OG001","value":"3.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)","description":"Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \\< 0.05). Frequency distributions will summarize the safety outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)","description":"Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p \\< 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":null},{"groupId":"OG001","value":"1.23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":38},"commonTop":["Fatigue"]}}}